Is acalatinib a targeted drug? What is its latest market price?

Acalabrutinib, an innovative drug developed by AstraZeneca, has shown significant efficacy in the treatment of specific blood tumors and has successfully received marketing approval. It offers new treatment hope specifically for adults with mantle cell lymphoma (MCL) who have received at least one prior treatment, and for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients are particularly concerned about whether this drug is a targeted drug and its current market price. This article will introduce this in detail.

Acotinib does belong to the category of targeted drugs. It is a highly selective inhibitor of Bruton's tyrosine kinase (BTK) and is a second-generation BTK inhibitor. BTKplays a key role in the B cell antigen receptor (BCR) signaling pathway, and abnormal activation of this signaling pathway is closely related to the occurrence and development of various B cell malignant tumors. By precisely inhibiting the activity of BTK, acotinib effectively blocks the conduction of the BCR signaling pathway, thereby inhibiting the proliferation and survival of malignant B cells and achieving the goal of treating tumors.

Regarding the current market price of acotinib, there may be certain differences in the specific price due to the influence of various factors such as region, sales channels, and medical insurance policies. in the country, the price of acotinib’s original drug is relatively high. According to public information, the retail price of capsules with specifications of 100mg*56 capsules is about more than 20,000 yuan.

However, thankfully, acotinib has been included in the national medical insurance directory. After patients enjoy medical insurance reimbursement, their financial burden will be relieved to a certain extent. However, the specific reimbursement ratio and reimbursement conditions vary from region to region, so patients need to consult the local medical insurance department to obtain accurate information.

In addition, with the rise of the generic drug market, generic drugs of acotinib have gradually entered the market. These generic drugs usually have a greater price advantage and can provide patients with more choices. However, when patients choose generic drugs, they should ensure that the drugs are from regular sources, of reliable quality, and used rationally under the guidance of a doctor. At present, each box of the Laos-ASEAN version of generic drugs is 100mg*60 tablets, and the price is about more than 3,000 yuan. In Bangladesh, the same specification version produced by Yaopin International sells for about 6,000 per box.

In short , acotinib, as a targeted drug, targetsBTKhas important value in the treatment of specific blood tumors. Although the current market prices vary due to various factors, the support of medical insurance policies and the rise of generic drugs have provided patients with more choices and financial support.